Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Forget · SciRah

Researcher profile · Semantic Scholar

F. Forget

Share profile

F. Forget — researcher profile on SciRah

h-index: 21
Works: 62
Citations: 2,286

Most-cited papers

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
F. Bidard, V. Kaklamani, P. Neven, G. Streich +25 more
2022Journal of Clinical Oncology594 citations Open access
Semantic Scholar
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
R. Coleman, D. Lorusso, C. Gennigens, A. González-Martín +19 more
2021The Lancet Oncology295 citations
Semantic Scholar
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
E. Quoix, H. Léna, G. Losonczy, F. Forget +18 more
2016The Lancet Oncology196 citations
Semantic Scholar
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
F. Rivera, M. Karthaus, J. Hecht, I. Sevilla +6 more
2017International Journal of Colorectal Disease124 citations Open access
Semantic Scholar
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
M. Colleoni, W. Luo, P. Karlsson, J. Chirgwin +248 more
2018The Lancet Oncology97 citations Open access
Semantic Scholar
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.
M. Oliveira, D. Pominchuk, Z. Nowecki, E. Hamilton +22 more
2024The Lancet Oncology85 citations
Semantic Scholar
Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
C. Ryan, M. Rosenthal, S. Ng, J. Alumkal +13 more
2012Clinical Cancer Research80 citations Open access
Semantic Scholar
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study
I. Vergote, E. Van Nieuwenhuysen, R. O'Cearbhaill, A. Westermann +27 more
2023Journal of Clinical Oncology74 citations Open access
Semantic Scholar
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
Eric S. Winer, H. Safran, B. Karaszewska, S. Bauer +6 more
2017International journal of hematology62 citations
Semantic Scholar
Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial
M. Oliveira, Denys Pominchuck, Z. Nowecki, E. Hamilton +23 more
2023Cancer Research61 citations
Semantic Scholar
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study
E. Winer, H. Safran, B. Karaszewska, D. Richards +8 more
2014Cancer Medicine52 citations Open access
Semantic Scholar
Skin Lesions in European Hibernating Bats Associated with Geomyces destructans, the Etiologic Agent of White-Nose Syndrome
G. Wibbelt, Sébastien J. Puechmaille, B. Ohlendorf, K. Mühldorfer +6 more
2013PLoS ONE50 citations Open access
Semantic Scholar
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
P. Harter, T. Johnson, D. Berton-Rigaud, Sang-Yoon Park +18 more
2016Gynecologic Oncology49 citations
Semantic Scholar
A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel : a promising combination in patients (pts) with solid tumors
M. Piccart-Gebhart, F. Branle, D. D. de Valeriola, M. Dubuisson +5 more
200145 citations
Semantic Scholar
Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study.
F. Mazzeo, L. Duck, E. Joosens, L. Dirix +8 more
2011Anticancer Research41 citations
Semantic Scholar
Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
A. Bardia, F. Bidard, P. Neven, G. Streich +23 more
2023Cancer Research35 citations
Semantic Scholar
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1
E. Ciruelos, H. Rugo, I. Mayer, C. Lévy +15 more
2021Journal of Clinical Oncology31 citations Open access
Semantic Scholar
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
R. O'Cearbhaill, J. Pérez-Fidalgo, B. Monk, I. Tusquets +21 more
2022Gynecologic Oncology28 citations Open access
Semantic Scholar
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study
P. Hillemanns, M. Zikán, F. Forget, H. Denys +13 more
2025Journal for ImmunoTherapy of Cancer24 citations Open access
Semantic Scholar
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.
H. Safran, P. Cassier, C. Vicier, F. Forget +16 more
2023Journal of Clinical Oncology22 citations
Semantic Scholar
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.
I. Vergote, P. Debruyne, F. Kridelka, P. Berteloot +12 more
2015Gynecologic Oncology22 citations
Semantic Scholar
LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
R. Coleman, D. Lorusso, C. Gennigens, A. González-Martín +16 more
2020Annals of Oncology21 citations Open access
Semantic Scholar
Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma
M. Peeters, F. Forget, M. Karthaus, M. Valladares-Ayerbes +4 more
2018ESMO Open20 citations Open access
Semantic Scholar
A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
F. Caroli-Bosc, J. V. van Laethem, P. Michel, F. Gay +3 more
2001European Journal of Cancer20 citations
Semantic Scholar
MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients
E. Stralen, R. Leguit, H. Begthel, L. Michaux +8 more
2009Leukemia17 citations Open access
Semantic Scholar
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer
B. Lim, D. Potter, M. Salkeni, P. Silverman +15 more
2021Clinical Cancer Research15 citations
Semantic Scholar
723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study
I. Vergote, B. Monk, R. O'Cearbhaill, A. Westermann +16 more
2021Annals of Oncology15 citations Open access
Semantic Scholar
Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy
C. Gennigens, M. de Cuypere, L. Seidel, J. Hermesse +5 more
2020Cancer Medicine14 citations Open access
Semantic Scholar
220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD
P. Aftimos, J. Cortes, F. Bidard, V. Kaklamani +16 more
2022Annals of Oncology11 citations Open access
Semantic Scholar
Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
A. Bardia, P. Neven, G. Streich, A. Montero +23 more
2022Cancer Research9 citations
Semantic Scholar
A randomized trial comparing best supportive care (BSC) versus multimodality approach (MA) to fight against cachexia in patients with cancer treated with chemotherapy.
F. Forget, N. Frusch, Lisbeth Trokay, Clemantine Archen +1 more
20149 citations
Semantic Scholar
A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC).
C. Ryan, M. Rosenthal, S. Ng, J. Alumkal +10 more
2012Journal of Clinical Oncology9 citations
Semantic Scholar
Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.
E. Quoix, F. Forget, Z. Pápai-Székely, C. Ottensmeier +8 more
20158 citations
Semantic Scholar
A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data
I. Vergote, Y. Humblet, E. Van Cutsem, S. Van Belle +6 more
20058 citations
Semantic Scholar
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
J. Thaler, R. Greil, Johannes Gaenzer, W. Eisterer +318 more
2015Annals of Oncology7 citations Open access
Semantic Scholar
Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study.
E. Winer, H. Safran, B. Karaszewska, D. Richards +8 more
20126 citations
Semantic Scholar
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).
V. Kaklamani, F. Bidard, P. Neven, A. Montero +16 more
2023Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).
V. Kaklamani, A. Bardia, P. Aftimos, J. Cortés +16 more
2022Journal of Clinical Oncology5 citations
Semantic Scholar
Anticancer chemotherapy in a patient with prior history of acute intermittent porphyria
F. Forget, A. Awada, J. Klastersky
2001Supportive Care in Cancer5 citations
Semantic Scholar
Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus
J. Diamond, D. Potter, M. Salkeni, P. Silverman +12 more
2019Poster Discussion Abstracts4 citations
Semantic Scholar
1055PDTIME, A PHASE 2B/3 STUDY EVALUATING TG4010 IN COMBINATION WITH FIRST LINE THERAPY IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC). PHASE 2B RESULTS.
E. Quoix, G. Losonczy, F. Forget, C. Chouaid +16 more
2014Annals of Oncology4 citations Open access
Semantic Scholar
TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results
E. Quoix, G. Losonczy, F. Forget, C. Chouaid +14 more
20144 citations Open access
Semantic Scholar
Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial.
J. Hoffman-Censits, M. Tsiatas, P. Chang, Miso Kim +16 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.
D. Juric, S. Loibl, F. André, J. I. D. Mingorance +12 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar
Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
R. O'Cearbhaill, J. Pérez-Fidalgo, B. Monk, I. Tusquets +21 more
2021Gynecologic Oncology2 citations
Semantic Scholar
P-149Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis
A. Sobrero, J. Douillard, F. Rivera, F. Forget +5 more
20162 citations Open access
Semantic Scholar
Safety and efficacy of eltrombopag (EPAG) vs placebo (PBO) for treatment of chemotherapy (CTx)-induced thrombocytopenia (TCP) in patients (Pts) with solid tumors receiving gemcitabine (GEM)-based CTx: A phase 2 study.
E. Winer, H. Safran, F. Forget, B. Karaszewska +7 more
20152 citations
Semantic Scholar
A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC).
C. Ryan, M. Rosenthal, S. Ng, J. Alumkal +10 more
2012Journal of Clinical Oncology2 citations
Semantic Scholar
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
J. Nemunaitis, Z. Pápai, H. Léna, G. Losonczy +13 more
2015Journal of Immunotherapy for Cancer1 citations Open access
Semantic Scholar
Phase 1/2 study of INCAGN01876, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers
Omid Hamid, F. Forget, Melissa L. Johnson, T. George +6 more
2026The Oncologist0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Neven×8
Invite
P. Neven — researcher profile on SciRah
F. Bidard×6
Invite
F. Bidard — researcher profile on SciRah
A. Montero×6
Invite
A. Montero — researcher profile on SciRah
H. Khong×6
Invite
H. Khong — researcher profile on SciRah

×6

Invite

F. Dalenc — researcher profile on SciRah

Invite

A. Bardia — researcher profile on SciRah

V. Kaklamani×5

Invite

V. Kaklamani — researcher profile on SciRah

Invite

G. Streich — researcher profile on SciRah

M. Mouret-Reynier×5

Invite

M. Mouret-Reynier — researcher profile on SciRah

Invite

J. Sohn — researcher profile on SciRah

Invite

D. Taylor — researcher profile on SciRah

Invite

K. Harnden — researcher profile on SciRah